CD133 was first reported to be a CSC marker for brain tumors by Singh et al. [10, 11], following which O’Brien et al. [12] demonstrated that colonic CSCs within the CD133(+) population have stem cell potential, allowing self-maintenance and differentiation as well as reestablishing tumor heterogeneity upon serial transplantation. This evidence concerns the gene PROM1 and neoplasm.